<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540539</url>
  </required_header>
  <id_info>
    <org_study_id>R1154-HV-1116</org_study_id>
    <nct_id>NCT01540539</nct_id>
  </id_info>
  <brief_title>Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and tolerability of intravenous (IV) and
      subcutaneous (SC) administration of REGN1154 in normal healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number and severity of TEAEs</measure>
    <time_frame>Day 1 through Day 113</time_frame>
    <description>TEAEs (Treatment-emergent adverse events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>Day 1 through Day 113</time_frame>
    <description>Serum concentrations of REGN1154 over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of antibodies</measure>
    <time_frame>Day 1 through Day 113</time_frame>
    <description>Presence or absence of antibodies against REGN1154 over time.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1154 or placebo</intervention_name>
    <description>Participants will receive active drug or placebo</description>
    <arm_group_label>Dosing cohort 1</arm_group_label>
    <arm_group_label>Dosing cohort 2</arm_group_label>
    <arm_group_label>Dosing cohort 3</arm_group_label>
    <arm_group_label>Dosing cohort 4</arm_group_label>
    <arm_group_label>Dosing cohort 5</arm_group_label>
    <arm_group_label>Dosing cohort 6</arm_group_label>
    <arm_group_label>Dosing cohort 7</arm_group_label>
    <arm_group_label>Dosing cohort 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women between the ages of 18 and 65; women must be postmenopausal or
             surgically sterile

          2. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive

          3. Willing, committed, and able to return for ALL clinic visits and complete all
             study-related procedures

          4. Able to read or to understand the consent process, and willing to sign the informed
             consent form (ICF)

        Exclusion Criteria:

        Exclusion criteria include, but are not limited to the following:

          1. Any illness or condition that would adversely affect the subject's participation in
             this study

          2. Any clinically significant abnormalities observed during the screening visit

          3. Use of certain medications taken before the screening visit

          4. Onset of a new exercise routine or major change to a previous exercise routine within
             4 weeks prior to screening visit

          5. Hospitalization within 60 days of the screening visit

          6. Any condition that would place the subject at risk, interfere with participation in
             the study

          7. History of or positive human immunodeficiency virus (HIV) screen result at the
             screening visit

          8. History of certain other conditions

          9. Positive urine, drug or alcohol screen result at screening

         10. Known sensitivity to any of the components of the investigational product formulation

         11. Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the
             investigational drug prior to the screening visit

         12. Live/attenuated vaccinations within 12 weeks of screening or during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

